I previously said that the year 2014 may be a game-changer for the 340B Drug Discount Program. Increasing HRSA audits, a lawsuit over the 340B Orphan Drug Rule, and HRSA’s promise to issue a 340B mega-regulation, all pointed to major changes in how the 340B Program operates.  However, the HRSA audits had limited effect, the court invalidated the Orphan Drug Rule, and the reverberations of the Orphan Drug litigation killed the 340B mega-regulation.

January 2018 began with a new 340B reimbursement rule and new litigation over that rule posing a very real threat to how hospitals use 340B drugs.  Then Congress issued a formal Report on legislative and regulatory modifications needed in the 340B Program.  Will 2018 finally be the game-changing year for 340B? Continue Reading This Year May be a Game Changer for 340B Drug Discount Program, Take Two

Happy New Year and welcome to 2018! Our first weekly preview of the year dives into the issues left unresolved in 2017. Where does CHIP and the minibus fit into the developing government funding bill, which Congress will have to finalize or pass another continuing resolution by January 19th. Also, the repeal of the individual mandate will have implications in the short- and long-term on health policy discussions. For our complete preview, please click here.

Americans today are facing an opioid epidemic that stems in part from the misuse of prescription drugs. CMS takes aim at this crisis in its CY 2019 Medicare Advantage and Part D  Proposed Rule (Proposed Rules) by setting out a framework for Part D plans to monitor and reduce the potential misuse of frequently abused prescription drugs. (Those interested in a high-level overview of the Proposed Rules should see our post from last month). Continue Reading Proposed Medicare Advantage and Part D Regulations for CY 2019 – CMS Takes on the Opioid Epidemic

Congress has its work cut out for itself between now and the end of the year. Between addressing the programs that constitute the Health Care Minibus, funding the government, and tax reform, there are also questions related to a market stabilization package (Alexander-Murray), the 340B program, the opioid epidemic, and another hurricane relief package. For the complete December preview, please click here.

It’s all about tax reform in Congress. This week, the House will look to pass its version of tax reform while the Senate begins marking up its package. Meanwhile, the end of the year is fast approaching and there are number of issues, including the health care minibus, that will need to be addressed. How Congress juggles the competing priorities and deadlines will be on display this week. You can read about this and more in the preview by clicking here.

The CHIP Reauthorization fight heads to the Senate where it faces an uncertain path forward as neither side can agree on payfors and the Senate Finance Committee focuses in on tax reform. While the Trump Administration is reportedly preparing an executive order that would eliminate the individual mandate, they are in a holding pattern to see if it gets included in the tax reform package. We cover that and more in our preview, which you can view here.

As the calendar turns to November, pressure continues to grow in Congress to pass a CHIP extension and address outstanding minibus extenders. Also on the radar is the first open enrollment period under the Trump Administration and the implications this could have for other policy issues. For the complete ML Strategies preview, please click here.

Last week, ML Strategies released an Advisory providing a comprehensive review of the sweeping health care legislation recently released by the Massachusetts Senate. The Advisory summarizes the notable provisions contained in the bill, including, among other things, how to handle the rising cost of prescription drugs, hospital reimbursement rates, changes to MassHealth (the Massachusetts Medicaid agency), and commercial insurance market tiering. The bill represents the latest in a series of proposals lawmakers and the Baker administration have made this year aimed at lowering health care costs and improving quality of care. Given the uncertain future of health care at the national level, all eyes will be on Massachusetts as it grapples with these important issues.

Our colleagues at ML Strategies have provided their Health Care Weekly Preview for the week of October 23, 2017. The preview discusses the Alexander-Murray stabilization package introduced by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA), and, in particular, where the stabilization package falls among Congress’ other priorities such as DACA and border security and what we are likely to see next.

Our colleagues at ML Strategies have provided their Health Care Weekly Preview for the week of October 16, 2017. The preview discusses the Administration’s decision to stop paying the cost-sharing reductions (CSRs) that plans have been receiving to cover lower-income individuals under the Affordable Care Act. It also discusses the suit that California and 18 other states and the District of Columbia have filed in response to the Administration’s decision on CSR payments.